Renal Cell Carcinoma | Unmet Need | Renal Cell Carcinoma – Metastatic Renal Cell Carcinoma | US/EU | 2016
Although there are several targeted agents approved for the treatment of metastatic renal cell carcinoma, including the approval of Opdivo by the FDA in November 2015, improvements in survival delivered by these therapies have only been incremental. Consequently, high unmet need still remains in the disease, and there is significant clinical and commercial opportunity for drug developers with new therapies that can extend patients’ lives compared to the current standard of care. This report provides an in-depth analysis of unmet need, examines the key drivers of prescribing behavior, and provides analysis of significant commercial opportunities for metastatic renal cell carcinoma.
Related Market Assessment Reports
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
